Lutetium-177, plus ipilimumab and nivolumab

The trial is called EVOLUTION.


This trial is adding to Lutetium-177 treatment, two immunotherapy drugs - the checkpoint inhibitors ipilimumab and nivolumab.


Immune checkpoints are key regulators of the immune system

Yervoy (ipilimumab) blocks checkpoint CTLA-4

Opdivo (nivolumab) and Keytruda (pembrolizumab) block checkpoint CD-1

Now mostly used for melanoma and lung cancer.

As you can see from the Contacts on the bible of clinical trials it is being offered in many hospitals around Australia.


It is being organised by the cross-Tasman research organisation ANZUP


https://clinicaltrials.gov/ct2/show/NCT05150236#contacts


4 views0 comments

Recent Posts

See All

This is my attempt to clarify the rules for PSMA PET/CT medicare coverage. I am not a doctor. A man may be entitled to Medicare coverage up to three times in a lifetime: Once before any direct treatme

A PSMA PET/CT scan can detect prostate cancer at very low levels. Indeed, when PSMA first became available, and not much was known about it, my doctor ordered the scan 'just to see what it shows' and